{
    "clinical_study": {
        "@rank": "166388", 
        "arm_group": [
            {
                "arm_group_label": "IDegAsp 15", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDegAsp", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IDeg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IAsp", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "IDeg + IAsp", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic\n      (exposure of the trial drug in the body) properties of insulin degludec/insulin aspart 15 in\n      subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index 18.0-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent\n             per day)\n\n          -  Not able or willing to refrain from smoking, use of nicotine substitute products or\n             transdermal nicotine patches during the inpatient period\n\n          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become\n             pregnant or is not using adequate contraceptive methods (adequate contraceptive\n             measures include sterilisation, hormonal intrauterine devices, oral contraceptives,\n             condom with spermizide, sexual abstinence or vasectomised partner)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773798", 
            "org_study_id": "NN1050-4008", 
            "secondary_id": [
                "2012-004215-31", 
                "U1111-1134-6222"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "IDegAsp 15", 
                "description": "Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).", 
                "intervention_name": "IDegAsp 15", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IDegAsp", 
                "description": "Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).", 
                "intervention_name": "IDegAsp", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDeg", 
                    "IDeg + IAsp"
                ], 
                "description": "Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).", 
                "intervention_name": "IDeg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IAsp", 
                    "IDeg + IAsp"
                ], 
                "description": "Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDegAsp 15", 
                    "IDegAsp"
                ], 
                "description": "Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 6, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8010"
                }
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Hastrup-Nielsen", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the glucose infusion rate curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 6 hours after single dose (IDegAsp 15, IDeg and IDegAsp)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773798"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum IDeg concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 120 hours after single dose"
            }, 
            {
                "measure": "Area under the serum IAsp concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 12 hours after single dose"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}